JP2021523185A - アレルゲンを含む改善されたｌａｍｐ構築物 - Google Patents

アレルゲンを含む改善されたｌａｍｐ構築物 Download PDF

Info

Publication number
JP2021523185A
JP2021523185A JP2020563907A JP2020563907A JP2021523185A JP 2021523185 A JP2021523185 A JP 2021523185A JP 2020563907 A JP2020563907 A JP 2020563907A JP 2020563907 A JP2020563907 A JP 2020563907A JP 2021523185 A JP2021523185 A JP 2021523185A
Authority
JP
Japan
Prior art keywords
lamp
improved lamp
cells
allergen
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020563907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523185A5 (enExample
Inventor
テリ ハイランド，
テリ ハイランド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomic Therapeutics Inc
Original Assignee
Immunomic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics Inc filed Critical Immunomic Therapeutics Inc
Publication of JP2021523185A publication Critical patent/JP2021523185A/ja
Publication of JP2021523185A5 publication Critical patent/JP2021523185A5/ja
Priority to JP2024001288A priority Critical patent/JP7742900B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43568—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from wasps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/4359—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from fleas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020563907A 2018-05-15 2019-05-14 アレルゲンを含む改善されたｌａｍｐ構築物 Withdrawn JP2021523185A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001288A JP7742900B2 (ja) 2018-05-15 2024-01-09 アレルゲンを含む改善されたｌａｍｐ構築物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862672005P 2018-05-15 2018-05-15
US62/672,005 2018-05-15
US201862672378P 2018-05-16 2018-05-16
US62/672,378 2018-05-16
US201862673932P 2018-05-20 2018-05-20
US62/673,932 2018-05-20
PCT/US2019/032305 WO2019222281A1 (en) 2018-05-15 2019-05-14 Improved lamp constructs comprising allergens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001288A Division JP7742900B2 (ja) 2018-05-15 2024-01-09 アレルゲンを含む改善されたｌａｍｐ構築物

Publications (2)

Publication Number Publication Date
JP2021523185A true JP2021523185A (ja) 2021-09-02
JP2021523185A5 JP2021523185A5 (enExample) 2022-09-01

Family

ID=66690998

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563907A Withdrawn JP2021523185A (ja) 2018-05-15 2019-05-14 アレルゲンを含む改善されたｌａｍｐ構築物
JP2024001288A Active JP7742900B2 (ja) 2018-05-15 2024-01-09 アレルゲンを含む改善されたｌａｍｐ構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001288A Active JP7742900B2 (ja) 2018-05-15 2024-01-09 アレルゲンを含む改善されたｌａｍｐ構築物

Country Status (5)

Country Link
US (1) US12398195B2 (enExample)
EP (1) EP3793595A1 (enExample)
JP (2) JP2021523185A (enExample)
CA (1) CA3100004A1 (enExample)
WO (1) WO2019222281A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022323847A1 (en) * 2021-08-03 2024-02-15 Ukko Inc. Hypoallergenic peanut allergens, production and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537285A (ja) * 2001-04-05 2004-12-16 ジョンズ・ホプキンス・ユニバーシティ キメラワクチン
JP2019537447A (ja) * 2016-11-16 2019-12-26 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルギーの治療のための核酸
JP2020517271A (ja) * 2017-04-22 2020-06-18 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 改良ｌａｍｐ構築物
JP2020518613A (ja) * 2017-05-02 2020-06-25 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 癌抗原を含む改善されたｌａｍｐ構築物

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237115A (en) 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4397844A (en) 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2026340B (en) 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4681762A (en) 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4593002A (en) 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4592002A (en) 1983-12-13 1986-05-27 Honeywell Inc. Method of digital temperature compensation and a digital data handling system utilizing the same
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
JPH06105020B2 (ja) 1992-06-09 1994-12-21 ホッペ・アーゲー ラッチ及びロックアップシステム
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
ATE277640T1 (de) 1994-03-07 2004-10-15 Dow Chemical Co Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
FR2719316B1 (fr) 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
EP0769063A1 (en) 1994-06-27 1997-04-23 The Johns Hopkins University Targeted gene delivery system
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU705035B2 (en) 1995-06-07 1999-05-13 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
WO1997035996A1 (en) 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
CZ438398A3 (cs) 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
AU3739697A (en) 1996-07-09 1998-02-02 Johns Hopkins University, The Gene delivery system
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
ATE353956T1 (de) 1996-12-13 2007-03-15 Schering Corp Methoden zur virus-reinigung
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
AU749032B2 (en) 1997-06-13 2002-06-20 Johns Hopkins University, The Therapeutic nanospheres
CA2242035C (en) 1997-07-01 2004-11-23 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
ES2180258T3 (es) 1998-07-07 2003-02-01 Transgene Sa Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US20070269457A1 (en) 2006-05-16 2007-11-22 The Buck Institute For Age Research Immunotherapeutic compositions and methods
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
EA023897B1 (ru) 2009-08-26 2016-07-29 Селекта Байосайенсиз, Инк. Композиции, которые индуцируют хелперное действие т-клеток
WO2011046996A2 (en) 2009-10-13 2011-04-21 The Johns Hopkins University Consensus sequence for influenza a virus
US20160185831A1 (en) 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2861240T3 (pl) 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
EP3157558A2 (en) 2014-06-23 2017-04-26 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537285A (ja) * 2001-04-05 2004-12-16 ジョンズ・ホプキンス・ユニバーシティ キメラワクチン
JP2019537447A (ja) * 2016-11-16 2019-12-26 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルギーの治療のための核酸
JP2020517271A (ja) * 2017-04-22 2020-06-18 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 改良ｌａｍｐ構築物
JP2020518613A (ja) * 2017-05-02 2020-06-25 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 癌抗原を含む改善されたｌａｍｐ構築物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARCHIVE OF BIOCHEMISTRY AND BIOPHYSICS, vol. 304, JPN6023017161, 1993, pages 65 - 73, ISSN: 0005263355 *
BMC BIOLOGY, vol. 10, JPN6023017160, 2012, pages 62, ISSN: 0005263354 *
JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2016, JPN6023017159, 2016, pages 4857869, ISSN: 0005263353 *
PLOS ONE, vol. 9, JPN6023017162, 2014, pages 99887, ISSN: 0005048500 *

Also Published As

Publication number Publication date
US20210261647A1 (en) 2021-08-26
US12398195B2 (en) 2025-08-26
JP2024024094A (ja) 2024-02-21
CA3100004A1 (en) 2019-11-21
WO2019222281A1 (en) 2019-11-21
JP7742900B2 (ja) 2025-09-22
EP3793595A1 (en) 2021-03-24
WO2019222281A9 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
JP7078620B2 (ja) アレルギーの治療のための核酸
US12116396B2 (en) LAMP constructs
JP2025160297A (ja) がん抗原を含む改良ｌａｍｐ構築物
JP7742900B2 (ja) アレルゲンを含む改善されたｌａｍｐ構築物
HK40123095A (en) Improved lamp constructs
HK40014081B (en) Improved lamp constructs
HK40014081A (en) Improved lamp constructs

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240215

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240221